T cell factor 1 (TCF-1) defines T cell differentiation in colorectal cancer

Kelly Tran,Anita N Kumari,Dinesh Raghu,Daniel R A Cox,Su Kah Goh,Marcos V Perini,Vijayaragavan Muralidharan,Niall C Tebbutt,Andreas Behren,John Mariadason,David S Williams,Lisa A Mielke
DOI: https://doi.org/10.1016/j.isci.2024.110754
IF: 5.8
2024-08-22
iScience
Abstract:The presence of precursor to exhausted (Tpex) CD8+ T cells is important to maintain robust immunity following treatment with immune checkpoint inhibition (ICI). Impressive responses to ICI are emerging in patients with stage II-III mismatch repair (MMR)-deficient (dMMR) colorectal cancer (CRC). We found 64% of dMMR and 15% of mismatch repair-proficient (pMMR) stage III CRCs had a high frequency of tumor infiltrating lymphocytes (TIL-hi). Furthermore, expression of TCF-1 (Tcf7) by CD8+ T cells predicted improved patient prognosis and Tpex cells (CD3+CD8+TCF-1+PD-1+) were abundant within lymphoid aggregates of stage III CRCs. In contrast, CD3+CD8+TCF-1-PD-1+ cells were more abundant at the invasive front and tumor core, while γδ T cells were equally abundant in all tumor areas. Interestingly, no differences in the frequency of Tpex cells were observed between TIL-hi dMMR and TIL-hi pMMR CRCs. Therefore, Tpex cell function and ICI response rates in TIL-hi CRC warrants further investigation.
What problem does this paper attempt to address?